Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Brookdale Senior Living (BKD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX – Research Report) and Brookdale Senior Living (BKD – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vertex Pharmaceuticals (VRTX)
Barclays analyst Eliana Merle maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $606.00. The company’s shares closed last Monday at $472.01.
According to TipRanks.com, Merle is a 4-star analyst with an average return of
Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $541.35, a 16.0% upside from current levels. In a report released today, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $536.00 price target.
See today’s best-performing stocks on TipRanks >>
Brookdale Senior Living (BKD)
In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Brookdale Senior Living, with a price target of $18.00. The company’s shares closed last Monday at $15.65.
According to TipRanks.com, CFA is a 1-star analyst with an average return of
Currently, the analyst consensus on Brookdale Senior Living is a Strong Buy with an average price target of $16.88, a 12.1% upside from current levels. In a report issued on January 29, TipRanks – Google also upgraded the stock to Buy with a $14.50 price target.
